Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
← catalyst calendarNCT07639684 · readout ≤ 1,015 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Feb 2027 | estimated | When the study began enrolling |
| Primary completion | May 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 2 Diabetes Mellitus (T2D)
- Obesity (BMI>30)
Intervention
- Device: ESG with OverStitch
Primary outcomes
what the primary-completion date above is the date OFSerious Adverse Events
measured Through study completion, 12 months post procedure
Average Change in HbA1c
measured 12 months post procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed